Sarcoidosis during infliximab therapy for Crohn's disease.
Tumor necrosis factor-alpha (TNF-alpha) antagonists are effective for inflammatory diseases, such as Crohn's disease, rheumatoid arthritis (RA) and psoriasis. Although TNF-alpha antagonists are also useful for sarcoidosis, paradoxical occurrence of sarcoidosis or sarcoidal reaction may be observed. We report a Crohn's disease patient, who developed sarcoidosis during infliximab therapy. A 35-year-old man had been receiving infliximab for 7 months for Crohn's disease. He developed cough and fever, accompanied by an infiltrated erythematous plaque on his right knee. The chest radiography, skin biopsy and laboratory findings were all consistent with sarcoidosis.
Takahashi
Hidetoshi
H
Department of Dermatology, Asahikawa Medical College, Asahikawa, Japan. hidetaka@psy.med.osaka-u.ac.jp
Kaneta
Kazuhiro
K
Honma
Masaru
M
Ishida-Yamamoto
Akemi
A
Ashida
Tomonori
T
Kohgo
Yutaka
Y
Ohsaki
Yoshinobu
Y
Iizuka
Hajime
H
D000328:Adult; D000893:Anti-Inflammatory Agents / Q000009:adverse effects*; D000911:Antibodies, Monoclonal / Q000009:adverse effects*; D003424:Crohn Disease / Q000188:drug therapy*; D006801:Humans; D000069285:Infliximab; D007717:Knee / Q000473:pathology*; D008297:Male; D012507:Sarcoidosis / Q000139:chemically induced* / Q000175:diagnosis; D016896:Treatment Outcome; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors
D000893:Anti-Inflammatory Agents; D000911:Antibodies, Monoclonal; D014409:Tumor Necrosis Factor-alpha; D000069285:Infliximab